Good afternoon everyone, and welcome to OraSure Technologies’ 2014 First Quarter Financial Results Conference Call and simultaneous Webcast. As a reminder, today’s conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer period. (Operator Instructions) OraSure Technologies issued a press release at approximately 4:00 PM Eastern Time today regarding its 2014 first quarter financial results and certain other matters. The press release is available on our Website at www.orasure.com or by calling 610-882-1820. If you go to our Website, the press release can be found by opening the Investor Relations page and clicking on the link for press releases. This call is also available real time on our Website and will be archived there for seven days. Alternatively, you can listen to an archive of this call until midnight May 14, 2014, by calling 855-859-2056 for domestic or 404-537-3406 for international. The access code is 31956599. With us today are Doug Michels, President and Chief Executive Officer; Ron Spair, Chief Operating Officer and Chief Financial Officer; and Kathy Weber, Senior Vice President and General Manager of Consumer Products. Doug and Ron will begin with opening statements, which will be followed with a question-and-answer session. Before I turn the call over to Doug, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, and other financial performance, product development, performance, shipments and markets, business plans and regulatory filings and approvals. Actual results could be significantly different. Factors that could affect results are discussed more fully in the Company’s SEC filings including its registration statements, its annual report on Form 10-K for the year-ended December 31, 2013, its quarterly reports on Form 10-Q, and its other SEC filings. Although forward-looking statements help to provide complete information about future prospects, listeners should keep in mind that forward-looking statements may not be reliable. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after this call. With that, I’d like to turn the call over to Doug Michels.

Great. Thanks, Rena, and good afternoon everyone, and welcome to our call. Earlier today, we issued a press release in which we announced our first quarter financial results for 2014. Consolidated net revenues for the quarter were $23.5 million, and a 11% improvement from the first quarter of 2013. The biggest contributor to this growth was our molecular collection systems businesses. That segment continues to deliver exceptional results with net quarterly revenues of $5.8 million, a 46% increase over 2013. Strong growth in our HCV business, higher sales of our OraQuick In-Home HIV test, and higher cryosurgical systems revenues also contributed to revenue growth in the quarter. We are very pleased with our first quarter results, and we expect continued strong performance throughout the remainder of 2014. Ron will begin with the financial review, and later in the call, I will provide some business updates. In particular, I will describe the changes we’re making to the promotional strategy for our OraQuick In-Home HIV test in order to improve the financial performance of this product. So with that, let me turn the call over to Ron to review our first quarter results and to update our guidance. Ron?

Okay. Thanks Doug, and good afternoon everyone. Our first quarter 2014 consolidated net revenues were $23.5 million compared to $21.2 million reported in 2013. Our consolidated product revenues increased 12% as a result of higher sales of our molecular collection systems, OraQuick HCV, OraQuick In-Home HIV, and our cryosurgical systems products. These increases were partially offset by lower sales of our OraQuick professional HIV product in the domestic market and our substance abuse and insurance risk assessment products. Our molecular collection systems revenues, primarily representing sales of the Oragene product line increased to $5.8 million in the first quarter of 2014 compared to $3.9 million in 2013. This 46% increase was the result of higher sales in both the commercial and academic markets. Our overall infectious disease testing revenues increased 4% to $11.1 million in the first quarter of 2014 compared to $10.7 million in the first quarter of 2013. Aggregate sales of our OraQuick HCV professional product in both the domestic and international markets increased 133%. International sales of our HCV test in the first quarter of 2014 increased to 896,000 from 240,000 in the same period last year, primarily due to sales and support of the significant testing program with an international NGO. Higher demand in the domestic market among new and existing customers contributed to the increase in sales of our HCV test in Q1 to 663,000 from 428,000 in the prior year. During the current quarter, net sales of our OraQuick In-Home HIV test were $2 million compared to $1.4 million in the first quarter of 2013. Net revenues for these periods were not recorded using the same revenue recognition policy and are not readily comparable. Due to our change in policy beginning in December 2013, revenues in the current quarter were recognized upon shipment to…

Thanks Ron, and let me start with our OraQuick HCV business. As Ron explained, this part of the business generated significant growth in the first quarter, largely reflecting the ongoing positive trends affecting HCV. Our aggregate estimated customer base increased as we added approximately 80 new customers during the quarter. On a worldwide basis, 17% of our revenues came from new customers. Our business is growing, and we see a good mix of sales from new and existing customers on a global basis. On the international front, a significant contributor to our growth is the large international NGO, which we’ve mentioned on prior calls, which has placed several large orders. I’m happy to report that this customer has indicated it’s intend to continue purchasing at comparable levels throughout 2014, and we expect this relationship will continue into next year. A CDC-funded outreach program by the AIDS Resource Center of Wisconsin used the OraQuick HCV Test to test over 1,000 patients. And an HCV testing initiative at the Wisconsin Division of Public Health reported in an MMWR issued by the CDC in April, tested over 1,200 individuals with our product. Each of these studies reported very high prevalence within their test groups, and because a rapid test was used, 100% of the individuals who tested positive received their results and were offered additional care. These studies each further confirm the important public health benefits that result when a rapid testing model is used. As previously noted, late last year the State of New York passed a law requiring the doctors offer hepatitis C testing as a routine part of healthcare provided to baby boomers. This law went into effect on January 1 this year and seems to have started a trend. There are now at least 10 states with HCV testing…

Thank you. (Operator Instructions) Our first question is from Jeff Frelick of Canaccord. You may begin.

Yes, thanks. Good afternoon folks, maybe a question for Ron first. Ron, on the step down in spending for HIV OTC, the profitability -- EPS profitability does that move up, should we expect to see that sooner and can you kind of give us a sense of maybe timing when that appears?

Right, so as Doug indicated, our expectations are moving from the $4.6 million worth of spend in Q1 to a $3.2 million spend in Q2, and then as we transition into the second half of the year our quarterly HIV OTC spend will be in the neighborhood of approximately $1 million or so, little less than that. And so as we transition away from that level of spending that we incurred historically we’re obviously moving more towards profitability here and with the HCV business continuing to grow with expectations for DNA Genotek and other parts of the business contributing it's all moving towards getting us to where we all want to be towards profitability.

Okay. On the HCV side, Doug you mentioned about 80 new customers added. Were those predominantly public health or some of those in the primary care setting, any color there you can share?

We saw growth really across all of the segments, when you look quarter-on-quarter. Public health overall was up more than 30%. The physician office group grew substantially and that’s good to see and international was up substantially as well. So, really pretty good growth across all the different segments.

And then, how about reorder rates for HCV customers, order’s that’s there?

It was strong. I think we mentioned in the prepared remarks order from new customers represented somewhere in the 17% range for the quarter, so the rest of that was all reorders from existing customers.

Okay, great, thanks. I’ll jump back in the queue.

Thank you. Our next question is from Brandon Couillard of Jefferies. You may begin.

Hi, this is Kate in for Brandon. Can we just go back to the DNAG business and maybe could you talk about some of the growth drivers behind the commercial portion of the business, and physically is there any bulk orders that you could call out?

Okay, great, thanks. And could you comment a timeline for a CE approval for the OTC products internationally and any comments on a go to market size either? Thanks.

I’ll let Kathy handle that question.

Yes, it's difficult to comment on the timeline for CE Mark approval because there are so many factors that go into that, review of the data, the regulatory process. So, as we said in the prepared remarks we’re actively pursuing CE Mark approval, and we’re also investigating the commercial possibilities and factoring in all the learning about the challenges in the U.S. market place, building awareness, driving new product behavior in terms of understanding what the commercial opportunity is there. So we’re in the midst of all those activities right now, it's just a little premature to definitely talk timing.

Okay, great. Thank you.

Thank you. Our next question is from Shaun Rodriguez of Cowen and Company. You may begin.

Hi, everyone, good afternoon. Thanks for taking the question. So on DNA Genotek you talked about a few different dynamics there and touched on 23andMe which was one of my questions; but I guess shaking it all out on last quarters call or maybe it was back when 23andMe issues got announced. You were talking about Genotek as the segment that could see modest growth for the year. So, I guess my question is after the Q1 result, is that how you would still characterize your expectations on a full-year basis or are they increased now?

Yes, I think we have to be careful not to get out in front of our skis on this one, right. So, we had real strong growth in the fourth quarter of 2013, we’re following that up with again real good growth in Q1 here. Going back to revenues last year, 23andMe began to kick-in in the second quarter and it was a strong contributor to revenues in Q3 and Q4. So, our comps now going forward are going to be a little more challenging with 23andMe in the 2013 revenues. So, I think we just have to be careful of that. We still expect growth from DNA Genotek; obviously we’re off to a real good start. I think we’re going to continue to see improvement in the academic business which is a real positive and first quarter was terrific with revenues up 30%. I think academic revenues actually were higher in first quarter of 2014 than they have been since 2012. They were certainly higher than any quarter that we had in 2013. So, the company continues to make good progress in bringing on new customers in both academic and the commercial space. The company continues to make good progress on their development programs with both the blood products, the sputum product and the microbiome project. So, we continue to be very pleased with how the team is performing up there and we expect good contributions for the rest of the year and then of course into 2015.

Okay, thanks. And then, Ron on Q2 guidance, does gross margin decline or does spend pick up anywhere, I guess what I’m getting at is, when I have sort of a mid-range revenue number in there and I bring the OTC spending down, I’m coming out at EPS numbers that are higher than where you guys are. So, is there anything in the mix or anything in spend outside of that line that’s changing sequentially that would get us there?

Yes, so I think we’ll see a little bit of an uptick in some of the R&D expenditures in the quarter Shaun that could contribute to that.

Okay. Sorry, I am jumping around, but did weather have any notable impact on just the core HIV or HCV OraQuick businesses in the quarter?

We believe it did, and I think you’re hitting on the major parts of our business that would be affected by weather in the public health sector in particular where different jurisdictions are going out into the community. They’re relying on gaining access to people in the different clinics and points of service. And if you think about some of our larger jurisdictions like New York, DC, Philadelphia, Atlanta, cities and communities that were in essence shutdown for weeks at a time, we estimate it probably had a dampening effect, maybe as high as 5% to 10%. Be careful though also to understand the short fall in the public health HIV business was due to a funding change that the CDC made to their grantees in 2014 and what happened there and this is unfortunate but we should catch up on this through the remainder of the year. Generally, when the CDC gives a grant notification to a jurisdiction that they’re being funded for a certain program, almost simultaneously with that grant notification they transfer the funds into that jurisdictions account. In March of this year they had a disconnect in that process and while grantees were notified of their award in -- I believe it was around March 11, many of those grantees didn’t actually get their funding until April, and it caused a real gap in terms of a number of jurisdictions ability to purchase product from us actually, a number of them actually ran out of tests and were out of the testing business for some time. Obviously those jurisdictions received their funding in April, and they will be able to catch up and we expect that, that catch up will come back to normal through the remainder of 2014 but that explains the vast majority of that first quarter short fall in the professional HIV business along with some weather impact that you mentioned.

Okay. And last one if I could, I guess I have to ask the question, although I think I’ve run out of creative ways to ask it, but on the HCV partnership front, can you give us any more color on those discussions. You said you’re still hopeful and I think that’s similar language that you’ve used in the past but are we any closer, is there any other color that you can provide on that? Thank you.

I tried to make it even a little more hopeful than I have in the past and highlighted that I think we made some real good progress, and hopefully we’ll have more to share on that in the near future.

Thank you.

You are welcome.

Thank you. (Operator Instructions) Our next question is from Nicholas Jansen of Raymond James. You may begin.

Hi, guys. A couple of quick ones for me, in terms of the domestic HCV performance, I would have thought that given the new launches and therapies you might have been up sequentially. So, I am just trying to get a sense of the timing of orders or how should we think about the domestic HCV performance throughout the balance of the year, maybe even what's included and kind of embedded into your 2Q outlook.

Yes, I think the way to look at that Nick is, in Q4 we saw some yearend spending, some extra money that the different jurisdictions had on hand, and that’s where we saw the major gap Q4 to Q1 here. Our expectation is that we’re going to see sequentially continued growth quarter-on-quarter through the remainder of 2014 and we expect to see a real strong growth year in Hepatitis C across each of the different market segments.

Okay, that’s helpful. And then kind of looking at the balance sheet $82 million, $83 million of cash. I know you guys have been active on the M&A front before, I just wanted to get your thoughts on, what areas of focus are you looking there, something accretive, something margin accretive, revenue accretive growth. Just trying to get a sense of how you’re viewing the M&A landscape.

Yes, thanks Nick. We are looking at opportunities that would be revenue generating and are at/or near being accretive to the bottom line. So that’s generally our view towards M&A. We are not necessarily interested in taking on a lengthy development project but rather an opportunity that is commercialized or very near commercialization that we can take advantage of.

Okay, and then last one for me, in terms of HIV OTC the decision to kind of cut back on spend. How do we think about the margin profile of that business as we look to our models in terms of kind of gross margin, the puts and takes for the next couple of quarters and into next year, there’s obviously a lot of moving parts with HCV and DNAG being higher gross margin businesses. I believe OTC was a lower gross margin business, so I’m just trying to get a better sense of the puts and takes.

Yes, so I think the gross margins on the product itself, won't necessarily be affected. We may do a little bit more trade spending as Kathy indicated. The product gross margin and the production cost is going to be the same. Some of those trade spends though will be deductive against our revenues which should drive down the gross margin from that product line a little bit, but not a significant amount. And then as Kathy had indicated expectations are, that over time that revenue will begin to grow again and obviously the spend levels will be much more muted when compared to what we have done over the last several quarters which will have much better profile economically for that product line.

Thanks guys. Nice quarter.

Good. Thanks.

Thanks Nick.

Thank you. Our next question is from Eric Criscuolo of Mizuho. You may begin.

Hi, good afternoon, just filling in for Peter Lawson this evening. I guess on the new manufacturing line’s that are coming up online; was there any capacity constraints this quarter that could have impacted sales for the molecular collection business?

No, there were not.

Okay, great. And then, on the funding for the CDC, do those public healthy labs did they typically buy in the March month or is it like did they wait for that something to come in, I’m just kind of curious because it seemed like it was delayed at the very end of the month, very end of the quarter. So, I just was kind of curious how their purchasing patterns kind of typically go?

They are sporadic, and they do follow the funding, believe it or not. And they generally purchase in large quantities which is an important distinction versus let’s say a hospital account or something like that. So they will buy a quarter, six months or sometimes some jurisdictions will be nine months’ worth of product at a time, and so that’s why these kinds of mismatches can have an impact on the business. Now, the funding is out right now, and so we don’t expect this to be an issue on a go forward basis, and for those jurisdictions that work without test for some period of time, their challenge is to now increase their recruiting efforts and their deployment efforts so that they can make up for those missed testing events within the communities in which they are serving, and that will take place over the next weeks and months.

Got it, and thanks for that color there. And then just lastly the cuts that you’re going to make for the OTC HIV sales and marketing campaign, is that money going to get plowed back into R&D or anything like that or is it substantially going to kind of fall to the bottom line?

I mean the cuts of that magnitude aren’t -- they will not be repurposed within the operating expense category. That said, we do as I mentioned before, expect to spend a little bit more in the R&D area in the second quarter here and that was likely to continue, but certainly not in the magnitude the cuts that are anticipated to be made in the HIV OTC program.

Thanks a lot.

Okay.

Thank you. That brings to an end the Q&A session of today's call. I would now turn the call over to Doug Michels for closing remarks.

Okay. I just want to thank everybody for joining us on the call this afternoon, this evening and we look forward to getting together again in a few months and talking about our results from the second quarter. Have a great afternoon and evening everyone. Thanks again.

Ladies and gentlemen this concludes today's conference. Thank you for your participation and have a wonderful day.